Atogepant for the Preventive Treatment of Chronic Migraine
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial
Lancet 2023 Jul 26;[EPub Ahead of Print], P Pozo-Rosich, J Ailani, M Ashina, PJ Goadsby, RB Lipton, U Reuter, H Guo, B Schwefel, K Lu, R Boinpally, R Miceli, R De Abreu Ferreira, E McCusker, SY Yu, L Severt, M Finnegan, JM TrugmanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.